Search
XORTX Therapeutics Inc
XRTXAdd to Watchlist
1.860USD
0.0000.00%
Market hours 09/22, 14:58（ET）
3.39MMarket Cap
LossP/E TTM
About XORTX Therapeutics Inc Company
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc Profile
Ticker SymbolXRTX
Company nameXORTX Therapeutics Inc
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 30
Address3710 - 33rd Street NW
CityCALGARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT2L 2M1
Phone14034557727
Websitehttps://www.xortx.com/
Ticker SymbolXRTX
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Company Executives of XORTX Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mika Grasso
Mr. Mika Grasso
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Depesh Narotam
Mr. Depesh Narotam
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of XORTX Therapeutics Inc?
The top five shareholders of XORTX Therapeutics Inc are: Ms. Krysta Davies Foss